by Rod Raynovich | Feb 23, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotech ETF’s and Major Indices are 5% off mid-January highs NADAQ stocks sold off for a second day but biotechnology stocks were mixed with a few winners.Major biotech ETF’s were down about 0.75% and off 5% from their 2011 highs in mid-January, the...
by Rod Raynovich | Feb 14, 2011 | 2024-25 Life Science Portfolios, BIOgraph
BIO CEO and Investor Conference Feb 14-15 Biotechnology stocks picked up some buying interest today from the BIO CEO Conference in NYC. CNBC provided some CEO clips from Exelixis (EXEL $10.58) up 7%, Onyxx(ONXX $36.28) up 0.28% and Optimer (OPTR $11.61) up 2.83%....
by Rod Raynovich | Feb 11, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Techs (QLD up 1.23%) outperformed biotechs today as Cisco bad news was forgotten. Biotech stocks treaded water today as all major ETF’s were flat. On the news front: Cephalon(CEPH $58.20) was down 3.17% on heavy volume as investors sold on there earnings report...
by Rod Raynovich | Feb 10, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotechnology Rally Underway The NASDAQ market recovered from near 1% losses today caused by the Cisco(CSCO) earnings report and guidance. The NASDAQ is currently flat to slightly down at 2785 recovering from the 2760 level. Expectations that Egypt’s President...
by Rod Raynovich | Feb 9, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Life Sciences Market Remains Strong while M&A Provides Support As we enter the peak earnings season for many tools and device companies, initial reports would indicate that investor expectations are higher and stocks could have a bit of profit taking. Genomic...
by Rod Raynovich | Feb 7, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Healthcare and Biotechnology stocks are underperforming the S&P YTD-Medical Devices and Equipment are a bright spot up over 4% YTD. The Q4 2010 momentum in biotech stocks has ebbed in 2011 as the broad market rally continues. The S&P is up 5% YTD while the...
by Rod Raynovich | Jan 21, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Time for Caution-Raise Cash After the Big Q4 2010 Run Here are some guidelines for the Rayno Life Science Portfolio: Smaller cap high beta biopharma stocks are at risk. No new buys. Our mid-cap index is still weak. Tools and diagnostics will be less volatile. ABAX,...
by Rod Raynovich | Jan 19, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Small to Mid Caps Off 3%+ Our Mid-Cap Index of biotech stocks was off 3% and more today. Among the big movers down on significant volume were: Alkermes (ALKS) down 4.19%, Arena (ARNA) down 4.25%, Biodel (BIOD) down 9.5%, Sangamo (SGMO) down 8.75%, Jazz (JAZZ) down...
by Rod Raynovich | Jan 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Review of the Laggards Celera (CRA $6.09) has been a laggard primarily because of disappointing results from the recent acquisition of Berkeley Heart Labs(BHL) which had reported sales $20M vs $24M in the previous quarter in 2009.Celera has a cumulative loss in the...
by Rod Raynovich | Jan 14, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Stay the Course for Now We will review our holdngs next week and rebalance if necessary. Overall it has been a good week with biotech indices up about 2%. Late January is always a good time for a correction but for now it is “don’t fight the FED,...
